CD274 and hepatocellular carcinoma: Additionally, immune checkpoint inhibitors have revolutionized HCC therapy with the approval of nivolumab and pembrolizumab targeting the PD-1/PD-L1 pathway for advanced HCC treatment, instilling new hope (8, 9).